Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamoxifen Citrate in Cystic Fibrosis
NCT07289035Phase 2Not yet recruiting
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Jan 2026
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tamoxifen in cystic fibrosis (CF), sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT07289035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07289035.